CL2013000502A1 - Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina. - Google Patents
Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.Info
- Publication number
- CL2013000502A1 CL2013000502A1 CL2013000502A CL2013000502A CL2013000502A1 CL 2013000502 A1 CL2013000502 A1 CL 2013000502A1 CL 2013000502 A CL2013000502 A CL 2013000502A CL 2013000502 A CL2013000502 A CL 2013000502A CL 2013000502 A1 CL2013000502 A1 CL 2013000502A1
- Authority
- CL
- Chile
- Prior art keywords
- alkyloxazole
- pyrrolidin
- carboxamide
- carbonyl
- benzyl
- Prior art date
Links
- -1 1- (2 (2-carbonyl-ethyl) benzyl) pyrrolidin-2-yl Chemical group 0.000 title 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 title 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/67—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/30—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37540610P | 2010-08-20 | 2010-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000502A1 true CL2013000502A1 (es) | 2014-01-03 |
Family
ID=44543856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000502A CL2013000502A1 (es) | 2010-08-20 | 2013-02-20 | Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8653118B2 (es) |
| EP (1) | EP2606044B1 (es) |
| JP (1) | JP5934212B2 (es) |
| KR (1) | KR20130092579A (es) |
| CN (1) | CN103119039A (es) |
| AR (1) | AR082492A1 (es) |
| AU (1) | AU2011291614B2 (es) |
| BR (1) | BR112013003884A2 (es) |
| CA (1) | CA2808798C (es) |
| CL (1) | CL2013000502A1 (es) |
| DK (1) | DK2606044T3 (es) |
| ES (1) | ES2485373T3 (es) |
| MX (1) | MX2013002031A (es) |
| PL (1) | PL2606044T3 (es) |
| RU (1) | RU2013111971A (es) |
| SG (1) | SG188245A1 (es) |
| TW (1) | TW201213323A (es) |
| WO (1) | WO2012024559A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR082492A1 (es) | 2010-08-20 | 2012-12-12 | Allergan Inc | N-alquil-2-(1-(5-sustituido-2-(3-oxo-3-(trifluorometilsulfonamido)propil)bencil)pirrolidin-2-il)oxazol-4-carboxamida y su uso para preparar un medicamento util para tratar enfermedades o afecciones mediadas por receptor dp, fp, ep, ep, tp y/o ep |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| EP2699565A1 (en) * | 2011-04-22 | 2014-02-26 | Allergan, Inc. | Fatty acid amide hydrolase inhibitors for treating pain |
| AU2012258780A1 (en) * | 2011-05-25 | 2013-12-19 | Allergan, Inc. | Fatty acid amide hydrolase inhibitors for treating pain |
| AP2016009020A0 (en) | 2013-07-18 | 2016-02-29 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
| CN107723304A (zh) * | 2016-08-10 | 2018-02-23 | 中国科学院上海生命科学研究院 | Prkar2a在炎症消退中的应用 |
| US20240382488A1 (en) * | 2021-03-29 | 2024-11-21 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| CN119013017A (zh) | 2022-02-15 | 2024-11-22 | 治纳辅医药科技有限公司 | 包含抗癌剂和对前列腺素e2受体具有抑制活性的新化合物的用于治疗癌症的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5280034A (en) * | 1991-08-23 | 1994-01-18 | E. R. Squibb & Sons, Inc. | Bis-heterocyclic prostaglandin analogs |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| ATE233743T1 (de) * | 1996-04-12 | 2003-03-15 | Searle & Co | N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren |
| AUPQ253199A0 (en) * | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| US7273883B2 (en) | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| US6511999B2 (en) | 2000-09-14 | 2003-01-28 | Allergan, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| US7217725B2 (en) | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US7045634B2 (en) * | 2003-09-05 | 2006-05-16 | Allergan, Inc. | Prostamide receptor antagonists |
| AR082492A1 (es) | 2010-08-20 | 2012-12-12 | Allergan Inc | N-alquil-2-(1-(5-sustituido-2-(3-oxo-3-(trifluorometilsulfonamido)propil)bencil)pirrolidin-2-il)oxazol-4-carboxamida y su uso para preparar un medicamento util para tratar enfermedades o afecciones mediadas por receptor dp, fp, ep, ep, tp y/o ep |
-
2011
- 2011-08-19 AR ARP110103017A patent/AR082492A1/es unknown
- 2011-08-19 TW TW100129849A patent/TW201213323A/zh unknown
- 2011-08-19 EP EP11751740.9A patent/EP2606044B1/en not_active Not-in-force
- 2011-08-19 US US13/817,949 patent/US8653118B2/en active Active
- 2011-08-19 SG SG2013012349A patent/SG188245A1/en unknown
- 2011-08-19 PL PL11751740T patent/PL2606044T3/pl unknown
- 2011-08-19 BR BR112013003884A patent/BR112013003884A2/pt not_active Application Discontinuation
- 2011-08-19 DK DK11751740.9T patent/DK2606044T3/da active
- 2011-08-19 RU RU2013111971/04A patent/RU2013111971A/ru not_active Application Discontinuation
- 2011-08-19 CN CN2011800447908A patent/CN103119039A/zh active Pending
- 2011-08-19 CA CA2808798A patent/CA2808798C/en active Active
- 2011-08-19 US US13/213,686 patent/US20120077858A1/en not_active Abandoned
- 2011-08-19 AU AU2011291614A patent/AU2011291614B2/en not_active Ceased
- 2011-08-19 MX MX2013002031A patent/MX2013002031A/es not_active Application Discontinuation
- 2011-08-19 JP JP2013524996A patent/JP5934212B2/ja not_active Expired - Fee Related
- 2011-08-19 WO PCT/US2011/048361 patent/WO2012024559A1/en not_active Ceased
- 2011-08-19 KR KR1020137006936A patent/KR20130092579A/ko not_active Withdrawn
- 2011-08-19 ES ES11751740.9T patent/ES2485373T3/es active Active
-
2013
- 2013-02-20 CL CL2013000502A patent/CL2013000502A1/es unknown
-
2014
- 2014-02-12 US US14/178,982 patent/US9085567B2/en active Active
-
2015
- 2015-07-06 US US14/792,406 patent/US9422273B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011291614A1 (en) | 2013-03-21 |
| US9085567B2 (en) | 2015-07-21 |
| CA2808798A1 (en) | 2012-02-23 |
| DK2606044T3 (da) | 2014-07-21 |
| US20130150417A1 (en) | 2013-06-13 |
| WO2012024559A1 (en) | 2012-02-23 |
| MX2013002031A (es) | 2013-05-17 |
| US20120077858A1 (en) | 2012-03-29 |
| KR20130092579A (ko) | 2013-08-20 |
| TW201213323A (en) | 2012-04-01 |
| US20140249192A1 (en) | 2014-09-04 |
| RU2013111971A (ru) | 2014-09-27 |
| EP2606044B1 (en) | 2014-06-04 |
| JP5934212B2 (ja) | 2016-06-15 |
| JP2013534254A (ja) | 2013-09-02 |
| AR082492A1 (es) | 2012-12-12 |
| PL2606044T3 (pl) | 2014-09-30 |
| AU2011291614B2 (en) | 2016-05-26 |
| US9422273B2 (en) | 2016-08-23 |
| ES2485373T3 (es) | 2014-08-13 |
| US20160068520A1 (en) | 2016-03-10 |
| BR112013003884A2 (pt) | 2016-06-07 |
| EP2606044A1 (en) | 2013-06-26 |
| SG188245A1 (en) | 2013-04-30 |
| CA2808798C (en) | 2020-04-28 |
| CN103119039A (zh) | 2013-05-22 |
| US8653118B2 (en) | 2014-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000502A1 (es) | Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina. | |
| SMT201500206B (it) | Composti spiro-ossindolici e loro uso come agenti terapeutici | |
| HUE039731T2 (hu) | l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére | |
| BRPI0913945A2 (pt) | agentes anti-inflamatórios | |
| CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| BRPI0719210A2 (pt) | Uso de compostos espiro-oxindol como agentes terapêuticos | |
| UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
| SMT201900656T1 (it) | Formulazioni di ketorolac pronte all'uso | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| IT1395519B1 (it) | Pezzo composito, nonche' impiego del pezzo composito | |
| EP2536762A4 (en) | INTEGRIN ALPHA V BETA 8 NEUTRALIZING ANTIBODY | |
| EP2694544A4 (en) | MONOCLONAL ANTIBODIES AGAINST INHIBITOR TISSUE FACTOR PATHWAY (TFPI) | |
| CL2013000735A1 (es) | Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico. | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| BRPI0913267A2 (pt) | uso do ácido succínico | |
| CL2008000110A1 (es) | Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos. | |
| BRPI0815596A2 (pt) | Uso de compostos de sulfonanilida como herbicida | |
| BRPI0911772A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| CL2008001795A1 (es) | Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial. | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| BRPI0807804A2 (pt) | " arilciclopentenos substituídos como agentes terapêuticos ". | |
| BR112013023575A2 (pt) | derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes | |
| ITMI20080195A1 (it) | Procedimento per la preparazione di solifenacin | |
| DE102008014880A8 (de) | Antientzündliches Polypeptid | |
| ITMI20072141A1 (it) | Procedimento per la preparazione del drospirenone |